These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 26377741)

  • 21. New antivirals for the treatment of chronic hepatitis B.
    Soriano V; Barreiro P; Benitez L; Peña JM; de Mendoza C
    Expert Opin Investig Drugs; 2017 Jul; 26(7):843-851. PubMed ID: 28521532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B Gene Therapy Coming to Age.
    Soriano V
    AIDS Rev; 2018; 20(2):125-127. PubMed ID: 29938706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Future anti-HBV strategies.
    Gane EJ
    Liver Int; 2017 Jan; 37 Suppl 1():40-44. PubMed ID: 28052637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological basis for functional cure of chronic hepatitis B.
    Martinez MG; Testoni B; Zoulim F
    J Viral Hepat; 2019 Jul; 26(7):786-794. PubMed ID: 30803126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.
    Mak LY; Wong DK; Cheung KS; Seto WK; Lai CL; Yuen MF
    Aliment Pharmacol Ther; 2018 Jan; 47(1):43-54. PubMed ID: 29035003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal management of hepatitis B virus infection - EASL Special Conference.
    Lampertico P; Maini M; Papatheodoridis G
    J Hepatol; 2015 Nov; 63(5):1238-53. PubMed ID: 26150256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B.
    Fung J; Lai CL; Yuen MF
    Expert Rev Anti Infect Ther; 2010 Jun; 8(6):717-26. PubMed ID: 20521898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA.
    Kumar R; Pérez-Del-Pulgar S; Testoni B; Lebossé F; Zoulim F
    Liver Int; 2016 Jan; 36 Suppl 1():72-7. PubMed ID: 26725901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
    Lampertico P; Viganò M; Colombo M
    Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment.
    Ruan P; Zhou B; Dai X; Sun Z; Guo X; Huang J; Gong Z
    Mol Med Rep; 2014 Apr; 9(4):1135-41. PubMed ID: 24566465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update in the management of chronic hepatitis B.
    Tujios SR; Lee WM
    Curr Opin Gastroenterol; 2013 May; 29(3):250-6. PubMed ID: 23519135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B.
    Chuaypen N; Posuwan N; Payungporn S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
    Liver Int; 2016 Jun; 36(6):827-36. PubMed ID: 26678018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
    J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Hepatitis B Core-Related Antigen.
    Inoue T; Tanaka Y
    Genes (Basel); 2019 May; 10(5):. PubMed ID: 31075974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations.
    Yuen MF; Ahn SH; Chen DS; Chen PJ; Dusheiko GM; Hou JL; Maddrey WC; Mizokami M; Seto WK; Zoulim F; Lai CL
    J Clin Gastroenterol; 2016 Apr; 50(4):286-94. PubMed ID: 26840752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
    Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New treatments to reach functional cure: Virological approaches.
    Durantel D
    Best Pract Res Clin Gastroenterol; 2017 Jun; 31(3):329-336. PubMed ID: 28774415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytes.
    Desmares M; Delphin M; Chardès B; Pons C; Riedinger J; Michelet M; Rivoire M; Verrier B; Salvetti A; Lucifora J; Durantel D
    Antiviral Res; 2022 Oct; 206():105386. PubMed ID: 35963549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developments in pharmacotherapeutic agents for hepatitis B - how close are we to a functional cure?
    Khan N; Almajed MR; Fitzmaurice MG; Jafri SM
    Expert Opin Pharmacother; 2023 Jun; 24(9):1001-1011. PubMed ID: 37163255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon therapy of chronic hepatitis B.
    Brunetto MR; Bonino F
    Intervirology; 2014; 57(3-4):163-70. PubMed ID: 25034484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.